Roche’s satralizumab significantly reduced relapse risk in positive phase III trial
Roche announced full pivotal phase III study results for satralizumab as a monotherapy for neuromyelitis optica spectrum disorder. Results from the SAkuraStar study show that satralizumab monotherapy achieved a 55% reduction in the risk of relapses compared to placebo. September 12, 2019